BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 780K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

16 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
61
Novel factor Xa inhibitors based on a benzoic acid scaffold and incorporating a neutral P1 ligand.EBI
Aventis Pharma Deutschland
6
Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.EBI
Aventis Pharma Deutschland
1
QSAR-by-NMR: quantitative insights into structural determinants for binding affinity by analysis of 1H/15N chemical shift differences in MMP-3 ligands.EBI
Aventis Pharma Deutschland
4
Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor.EBI
Aventis Pharma Deutschland
28
Structure-based design of amidinophenylurea-derivatives for factor VIIa inhibition.EBI
Aventis Pharma Deutschland
29
Pharmacophore-based search, synthesis, and biological evaluation of anthranilic amides as novel blockers of the Kv1.5 channel.EBI
Aventis Pharma Deutschland
22
Design, synthesis, and structure-activity relationship of a new class of amidinophenylurea-based factor VIIa inhibitors.EBI
Aventis Pharma Deutschland
29
Identification, synthesis, and activity of novel blockers of the voltage-gated potassium channel Kv1.5.EBI
Aventis Pharma Deutschland
85
Structural classification of protein kinases using 3D molecular interaction field analysis of their ligand binding sites: target family landscapes.EBI
Aventis Pharma Deutschland
17
Synthesis and activity of novel and selective I(Ks)-channel blockers.EBI
Aventis Pharma Deutschland
32
alpha(v)beta(3) Antagonists based on a central thiophene scaffold.EBI
Aventis Pharma Deutschland
4
Structural basis for the highly selective inhibition of MMP-13.BDB
Aventis Pharma Deutschland
22
Factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of neutral P1 substituents.BDB
Aventis Pharma Deutschland
27
Novel factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of P4 substituents in combination with a neutral P1 ligand.BDB
Aventis Pharma Deutschland
83
Design and quantitative structure-activity relationship of 3-amidinobenzyl-1H-indole-2-carboxamides as potent, nonchiral, and selective inhibitors of blood coagulation factor Xa.BDB
Aventis Pharma Deutschland
107
Structural requirements for factor Xa inhibition by 3-oxybenzamides with neutral P1 substituents: combining X-ray crystallography, 3D-QSAR, and tailored scoring functions.BDB
Aventis Pharma Deutschland